Please assess the completion status of the following clinical trial:

Trial Title: A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Volunteered to participate in this study and signed informed consent.~* Age 18-70 years old, male or female.~* Relapse or refractory B cell non-Hodgkin's lymphoma ,Histologically diagnosed as DLBCL,follicular lymphoma and Mantle cell lymphoma according to the NCCN. nonHodgkin's lymphoma Clinical Practice Guidelines (2017 Version 1)~  1. DLBCL and Follicular Lymphoma (stage Ⅲ-Ⅳ, grade Ⅲb).~     1. Progressive disease after the last standard chemotherapy regimens.~    2. Stable disease after the last standard chemotherapy regimens(at least 4 cycles of first-line therapy or 2 cycles of later-line therapy).~    3. Relapse or progressive disease within 12 months after autologous stem cell transplantation (SCT).~ 2. Follicular lymphoma (stage Ⅲ-Ⅳ) (gradeⅠ-Ⅲa)~     1. Relapse or progressive disease within 1 year after the last standard chemotherapy regimens(At least 2 combination chemotherapy regimens).~    2. Stable disease after the last standard chemotherapy regimens(at least 2 cycles of combination chemotherapy regimens).~ 3. Mantle cell lymphoma~     1. Relapse after 1st CR or persistent disease, and not eligible or appropriate for SCT.~    2. Relapse or progressive disease within 1 year after the last chemotherapy regimens(at least 4 cycles of first-line therapy or 2 cycles of later- line therapy).~    3. Relapse or progressive disease within 12 months after autologous SCT.~* All subjects must have received anti-CD20 monoclonal antibody (unless tumor is CD20-negative) and anthracycline-containing chemotherapy regimens according to NCCN non-Hodgkin lymphoma Clinical Practice Guidelines (2017 Version 1).~* At least one measurable lesion per revised IWG Response Criteria (the longest diameter of the tumor ≥ 1.5cm).~* Expected survival ≥ 12 weeks.~* ECOG score 0-1.~* Left ventricular ejection fraction (LVEF) ≥ 50% (detected by echocardiography).~* No active pulmonary infections, normal pulmonary function and oxygen saturation ≥ 92% on room air.~* At least 2 weeks from receiving previous treatment (radiotherapy or chemotherapy) prior to leukapheresis.~* No contraindications of leukapheresis.~* Female subjects in childbearing age, their serum or urine pregnancy test must be negative, and must agree to take effective contraceptive measures during the trial.~Exclusion Criteria:~* History of allergy to cellular products.~* Laboratory tests: absolute neutrophil count \< 1.0 × 10\^9 /L, platelet count \< 50×10\^9 /L, serum albumin \< 30 g/L,serum bilirubin \> 1.5 ULN, serum creatinine \> ULN, ALT/AST \> 3 ULN.~* History of CAR T cell therapy or any other genetically modified T cell therapy.~* Relapse after allogeneic hematopoietic stem cell transplantation.~* Active infections that require treatment (uncomplicated urinary tract infections and bacterial pharyngitis are allowed), prophylactic antibiotic, antiviral and antifungal treatment are permitted.~* Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as acquired or congenital immune deficiency diseases, including but not limited to HIV infection.~* Class III or IV heart failure according to the NYHA Heart Failure Classifications.~* QT interval prolongation ≥ 450 ms.~* History of epilepsy or other central nervous system disorders.~* Evidence of CNS lymphoma by head enhancement scan or magnetic resonance imaging.~* History of other primary cancers, with the following exceptions.~  1. Excisional non-melanoma (e.g. cutaneous basal cell carcinoma).~ 2. Cured in situ carcinoma (e.g. cervical cancer, bladder cancer, breast cancer).~* Autoimmune diseases that require treatment, immune deficiency diseases or other diseases that require immunosuppressive therapy.~* Used of systemic steroids within two weeks (using inhaled steroids is an exception).~* Women who are pregnant or lactating, or who have breeding intent in 6 months.~* Participated in any other clinical trial within three months.~* Any situation that investigators believe the risk of the subjects is increased or results of the trial are disturbed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CD19-directed CAR-T cells (Type: EXPERIMENTAL): Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete